IP Library Granted Patent US 10,807,944
Granted Patent B2
US 10,807,944 · App. 15/301,508 · Granted Oct 20, 2020

HDAC inhibitor compounds and methods of treatment

Inventors: Daiqing Liao (Gainesville, FL); William R. Roush (Jupiter, FL); Ryan L. Stowe (Jupiter, FL)
Assignees: University of Florida Research Foundation, Inc.; The Scripps Research Institute
C07C233/77A61K31/166A61K31/4406A61K31/505A61K45/06C07C233/78C07C243/38C07C247/12C07D213/44C07D213/86C07D239/26C07D239/48C07C2601/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,807,944
App. No.
15/301,508
Granted
Oct 20, 2020
Kind
B2
Abstract

The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

Claims (38)

1. A compound according to Formula I, or a salt thereof:

wherein:

X is CH;

Y is C—R 3 ;

R 1 is H, halo, optionally substituted aryl, optionally substituted alkyl, haloalkyl, alkoxy, nitro, haloalkoxy,

R 2 is H, halo, optionally substituted aryl, optionally substituted alkyl, haloalkyl, alkoxy, nitro, haloalkoxy,

R 3 is optionally substituted heteroaryl, NMe 2 , t-Bu,

or aryl optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, arylsulfonyl, alkylaminocarbonyl, alkylcarbonyl, aralkylaminocarbonyl, amido, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, carbamido, carbamyl, thioureido, thiocyanato, sulfoamido, sulfonylalkyl, or sulfonylaryl;

R 4 is H or OH;

R 5 is alkyl optionally substituted with cycloalkyl; and

R 6 and R 7 are each independently H or optionally substituted alkyl.

2. The compound of claim 1 , wherein R 1 and R 4 are H.

3. The compound of claim 1 , wherein R 1 and R 4 are H; and R 5 is C 1 -C 6 alkyl or (cycloalkyl)alkyl.

4. The compound of claim 1 , wherein R 1 and R 4 are H; and R 5 is n-Pr, n-Bu, n-pentyl, n-hexyl,

5. The compound of claim 1 , wherein R 1 , R 2 , and R 4 are H; and R 5 is n-Bu,

6. The compound of claim 3 , wherein R 2 is alkoxy.

7. The compound of claim 1 , wherein the compound is selected from the group consisting of:

N′-butyl-4-(dimethylamino)benzohydrazide (RLS2-131);

N′-(cyclopentylmethyl)-4-(dimethylamino)benzohydrazide (RLS2-225);

4-(azidomethyl)-N′-butylbenzohydrazide (RLS2-312);

N′-pentylbiphenyl-4-carbohydrazide (RLS3-43)

N′-butyl-4-(pyrimidin-5-yl)benzohydrazide (SR-4369);

N′-butyl-2′,3′-difluorobiphenyl-4-carbohydrazide (SR-4370);

N′-butyl-3′-fluoro-5′-methylbiphenyl-4-carbohydrazide (SR-4372); and

ethyl 4′-(2-butylhydrazinecarbonyl)-6-fluorobiphenyl-3-carboxylate (SR-4373).

8. A pharmaceutical composition comprising the compound of formula I and a pharmaceutically acceptable carrier:

wherein:

X is CH;

Y is C—R 3 ;

R 1 is H, halo, optionally substituted aryl, haloalkyl, alkoxy, nitro, haloalkoxy,

R 2 is H, halo, optionally substituted aryl, optionally substituted alkyl, haloalkyl, alkoxy, nitro, haloalkoxy,

R 3 is optionally substituted heteroaryl, NMe 2 , t-Bu,

or aryl optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, arylsulfonyl, alkylaminocarbonyl, alkylcarbonyl, aralkylaminocarbonyl, amido, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, carbamido, carbamyl, thioureido, thiocyanato, sulfoamido, sulfonylalkyl, or sulfonylaryl;

R 4 is H or OH;

R 5 is alkyl optionally substituted with cycloalkyl; and

R 6 and R 7 are each independently H or optionally substituted alkyl.

9. The pharmaceutical composition of claim 8 further comprising an anti-cancer agent, a chemotherapeutic agent, or an anti-angiogenesis agent.

10. The pharmaceutical composition of claim 9 wherein the chemotherapeutic is selected from daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil, 5-fluorodeoxyuridine, methotrexate, colchicine, vincristine, vinblastine, etoposide, trimetrexate, teniposide, cisplatin, and diethylstilbestrol.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: THE SCRIPPS RESEARCH INSTITUTE
To: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Reel/Frame 060449/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 060450/0001 →
CONFIRMATORY LICENSE Recorded Apr 16, 2018
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045944/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2016
From: LIAO, DAIQING
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 040368/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2016
From: ROUSH, WILLIAM R.; STOWE, RYAN L.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 040369/0457 →
Continuity (3)
Provisional Application 62117326 · Feb 17, 2015
Provisional Application 61975564 · Apr 4, 2014
Related Publication 20170174619A1 · Jun 22, 2017